Synapse: Law for Life Sciences — March 2013
This month on Synapse, Taylor Wessing discusses the impact of insolvency on licensors and licensees in the life sciences sector. This sector is feeling the pressure for a number of well-documented reasons — a difficult funding environment, a challenging regulatory landscape and dwindling pipelines — and these all, sadly, mean that insolvencies in the sector are happening and will continue to happen.
So it is prudent for any life sciences company to consider the potential impact of the insolvency of its counterparty in each agreement that it enters into. This article considers, in particular, the impact on intellectual property licences.
The Insolvency Act 1986, as amended, along with the Companies Act 2006, provides a comprehensive toolbox of different procedures that creditors and debtors may take advantage of…
If you are registered and logged in to the site, click on the link below to read the rest of the Taylor Wessing briefing. If not, please register or sign in with your details below.
News from Taylor Wessing
News from The Lawyer
Briefings from Taylor Wessing
The Düsseldorf Court of Appeal has referred questions to the CJEU on whether the supply of patent-protected substances by a third party to a generic company is covered by the Bolar exemption.
This is only the second time that the Data Protection Index has featured in Global Intellectual Property Index, yet a number of trends are already apparent from the results.
Analysis from The Lawyer
The city-state is working hard to become a global wealth management hub, and law firms are gearing up for a prosperous new world
Financial disputes are starting to dominate the English courts as the long-awaited fallout from the downturn finally comes to town